home about team portfolio news investor login contact


 MENLO PARK, Calif. – November 9, 2010– Panorama Capital, a Silicon Valley-based venture capital firm, today announced the promotions of Shankar Chandran and Gaurav Aggarwal to partner. 

 "Shankar and Gaurav have made exceptional contributions to the firm and the companies with whom they work,” said Rod Ferguson, managing director at Panorama Capital.  "I am enthusiastic about them as partners who will help lead the firm into the next decade."  Both Chandran and Aggarwal were previously principals with the firm and will continue to invest in startups and help entrepreneurs build market leading, category defining companies.

Shankar Chandran leads Panorama’s efforts in the core technology sector, investing in companies developing the critical components and systems enabling the convergence of mobile technology and the web. Shankar has been a principal with the firm since its founding in 2005 and worked closely with the team since 2002 at JPMorgan Partners. He currently serves on the board of directors of Validity, CHiL Semiconductor and Neoconix. Previously, Shankar was involved either as a director or observer with the firm’s investments in Reflectivity (acquired by TI), Valere Power (acquired by Eltek) and Portalplayer (acquired by Nvidia). 

Prior to his venture capital career, Shankar had extensive operating experience, holding various engineering, business development, and management roles at Applied Materials.  He has been granted seven patents. Shankar serves on the Advisory Board of Center for Innovation and Entrepreneurship at the Santa Clara University and holds a B.Tech in Metallurgical Engineering from the Institute of Technology, BHU (India), an M.S. in Materials Science from Arizona State University, and an M.B.A. from The Wharton School of the University of Pennsylvania.

A physician by training, Gaurav Aggarwal invests in emerging life sciences companies and has been part of the firm as a principal since its founding.  He too worked with the team while at JPMorgan Partners.  He currently serves on the board of directors of Alvine Pharmaceuticals and Hyperion Therapeutics, and was previously on the board of directors at Flowcardia (acquired by Bard) and PIramed (acquired by Roche).  Gaurav was also closely involved in the firm’s investments in Amarin Corporation and Presidio Pharmaceuticals.

Previously, Gaurav was at KBL Healthcare Ventures, where he focused on venture investments in biopharmaceutical and medical device companies.  There he served as a board observer with KBL's investments in Achillion Pharmaceuticals, ISTA Pharmaceuticals, Neuronetics and Spinal Concepts and was involved with KBL's investments in Corixa Corporation and Scynexis.  Gaurav received his M.D. from Columbia University, College of Physicians & Surgeons and his B.S. in Business Management from Cornell University.

 About Panorama Capital

Panorama Capital is a Silicon Valley venture capital firm that invests in passionate entrepreneurs building leading companies in technology and life sciences. Panorama takes a hands-on approach to investing, helping companies accelerate their growth.  We bring to each portfolio company our knowledge as seasoned investors who also possess a wealth of experience as executives, entrepreneurs, engineers and physicians. This experience gives Panorama Capital a powerful combination of technical, operational and transactional expertise to help our companies succeed.  For more than two decades, the Panorama Capital team has invested in and helped build more than 100 companies, more than 60 of which went public or were acquired.  For more information about Panorama Capital, visit www.panoramacapital.com.